Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (August 2017)
13 slides from Pyc Therapeutics's investor presentation, Aug 21, 2017
Slide 1: Phylogica Investor Briefing
For personal use only Phylogica Investor Briefing August 2017 Stephanie Unwin, Chief Executive Officer
Slide 2: Disclaimer
Disclaimer The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) [‘Phylogica’]. For personal use only These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc
Slide 3: Corporate profile
Corporate profile Phylogica stock price, AUD Directors For personal use only Stephanie Unwin Chief Executive Officer 0.06 Dr Robert Hayes, PhD Executive Director 0.04 Dr Bernard Hockings Non-Executive Director 0.02 Dr Rick Kendall Non-Executive Director Dr Paul Watt Non-Executive Director 0 Dr Rohan
Slide 4: Highly valuable intracellular target space remains untapped
Highly valuable intracellular target space remains untapped 80% of drug targets are inside cells but only 10% of such targets Phylogica’s FPP platform finds peptides which can break For personal use only are druggable through the cell membrane (Endosomal escape) Distribution of drug targets Market f
Slide 5: Phylomer FPPs are able to deliver a diverse range and size of cargos
Phylomer FPPs are able to deliver a diverse range and size of cargos Conceptual stage Example cargos and targeted diseases that can be delivered with FPPs Validated efficacious delivery For personal use only Cargo class Example cargo Example disease Progress1 Cargo size RNA PMO Duchenne muscular dys
Slide 6: Phylogica has had early success in developing FPPs and Myc
Phylogica has had early success in developing FPPs and Myc ▪ Phylomer screens against validated and clinically relevant oncology targets Lead program – c-Myc, N-Myc, Stat5 and YB1 ▪ Validated hits already exceed potency of gold standard inhibitors For personal use only ▪ Stat5 and YB 1 collaboration
Slide 7: Jan – In Vivo efficacy data to validate a functioning FPP platform
Jan 18 – In Vivo efficacy data to validate a functioning FPP platform three focus areas - increase potency of FPP-iMyc For personal use only drug conjugate 1 ▪Improve FPP’s endosomal escape activity New FPPs to be identified by assays ▪ Protein engineering work Outcome: improved – Fine tuning existi
Slide 8: Dr Robert Hayes, Chief Scientific Officer
Dr Robert Hayes Chief Scientific Officer Ph.D. in Protein Biochemistry from Imperial College, London For personal use only Royal Society University Fellow, Royal College of Science Scholar Postdoc work at UC Berkeley in protein engineering In 1998, joined a start-up in Berkeley called Xencor
Slide 9: Current activities – FPP Platform Validation
Current activities – FPP Platform Validation Example: β-lactamase FPP assay For personal use only Goals FPP-Cargo • Provide optimised FPPs for the oncology program • Develop better understanding of FPP delivery FPP-Cargo • Further validation of the FPP platform The FPP program FPP discovery • Scre
Slide 10: Current activities: Oncology MYC program, validation of iMycs
Current activities: Oncology MYC program, validation of iMycs Oncology program aims to prove that Phylomers can be targeted to proteins inside cells that are important in cancer development and For personal use only progression (oncoproteins such as MYC) Testing of MYC inhibitors: can our Phylom
Slide 11: Current activities: Oncology MYC program, affinity maturation, MOA and PD markers
Current activities: Oncology MYC program, affinity maturation, MOA and PD markers Oncology program aims to prove that Phylomers can be targeted to proteins inside cells that are important in cancer development and progression (oncoproteins such For personal use only as MYC) – Affinity maturation o
Slide 12: FPP delivery of an oligonucleotide in vivo in a model of DMD
FPP delivery of an oligonucleotide in vivo in a model of Duchenne muscular dystrophy (DMD) Histology staining For personal use only DMD, a X-linked recessive neuromuscular disorder, leads to severe muscle wasting – by the age of 12 most boys are unable to walk DMD is caused by a mutation of the
Slide 13: Current activities: Genentech Collaboration
Current activities: Genentech Collaboration Project with Genentech (Roche) – leading biotechnology company in the US Our collaboration aims at the isolation of Phylomers that can help killing multi-drug resistant “super bugs” For personal use only – Phylomers are expected to increase the potenti